Drugs / IPP-204106N
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01711398 | Jul 2012 → Sep 2014 | high grade malignant neoplasm | Elro Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPP-204106N | “A Non-randomized, Open-label, Multi-centric Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Repeated...” NCT01711398 ↗ |
| Route | Intravenous | “Repeated Intravenous IPP-204106N Administrations” NCT01711398 ↗ |